transmiss
gastroenter
viru
tgev
neutral
antibodi
singl
specif
monoclon
antibodi
mab
viru
neutral
first
min
revers
reaction
follow
second
phase
decreas
neutral
rate
case
persist
fraction
function
mab
antibodytoviru
ratio
neutral
tgev
specif
event
requir
locat
epitop
involv
neutral
appropri
structur
context
present
wildtyp
viru
certain
mab
escap
mutant
neutral
tgev
binari
combin
mab
specif
differ
antigen
site
either
cooper
synergist
effect
respect
observ
mechan
tgev
neutral
mab
character
high
intermedi
low
antibodytoviru
ratio
condit
mainli
three
step
replic
cycl
inhibit
bind
viru
cell
intern
step
take
place
intern
addit
viru
aggreg
could
respons
neutral
viru
infect
porcin
transmiss
gastroenter
tge
enter
diseas
swine
associ
high
mortal
neonat
caus
coronaviru
consist
singlestrand
positivesens
rna
molecul
kb
three
structur
protein
n
amino
acid
respect
siddel
et
al
sturman
holm
salt
bahl
kapk
brian
laud
et
al
rasschaert
laud
coronavirus
protein
respons
induct
neutral
antibodi
garw
et
al
garw
et
al
sturman
holm
studi
antigen
structur
prototyp
coronavirus
mous
hepat
viru
infecti
bronchiti
viru
tgev
shown
least
two
critic
site
involv
neutral
talbot
et
al
wage
et
al
mockett
et
al
fleme
al
delmasat
tgev
glycoprotein
involv
viru
neutral
absenc
complement
protein
minimum
seven
antigen
site
defin
site
major
induc
neutral
antibodi
although
site
b
less
immunogen
also
involv
tgev
neutral
enjuan
et
al
delma
et
al
correa
et
al
addit
antibodymedi
complementdepend
viru
neutral
report
mspecif
request
reprint
address
monoclon
antibodi
mab
wood
et
al
laud
et
al
viru
neutral
achiev
inhibit
step
viru
replic
dimmock
dimmock
tgev
littl
known
mechan
neutral
one
report
nguyen
et
al
suggest
neutral
tgev
secretari
iga
milk
igg
serum
due
inhibit
intern
adsorb
viru
blockag
viru
bind
host
cell
paper
character
mechan
neutral
tgev
monoclon
polyclon
antibodi
high
intermedi
low
antibodytoviru
ratio
cell
viru
epitheli
swine
testicl
cell
line
st
develop
mcclurkin
norman
use
grow
purdu
strain
tgev
bullido
et
al
sanchez
et
al
plaqu
purifi
jimenez
et
al
viru
neutral
purif
two
procedur
follow
plaqu
reduct
assay
one
fix
amount
tgev
pfu
incub
antibodi
dilut
virusantibodi
mixtur
plaqu
second
dilut
viru
incub
fix
amount
antibodi
mixtur
appli
cell
without
dilut
plaqu
reduct
assay
perform
incub
min
unless
otherwis
indic
tgev
pl
phosphatesuw
et
al
buffer
salin
pb
contain
fetal
calf
serum
vol
mab
antiserum
dilut
portion
contain
mixtur
appli
cell
monolay
grown
micropl
hr
viru
adsorpt
inoculum
replac
medium
contain
fetal
calf
serum
deaedextranml
agaros
cell
incub
day
humidifi
co
incub
cell
fix
formaldehyd
stain
crystal
violet
plaqu
count
extent
neutral
express
neutral
index
ni
log
ratio
number
pfu
viru
control
medium
antibodi
h
leucineor
methioninelabel
tgev
grown
dulbecco
modifi
eagl
dme
medium
complet
partial
deplet
leucin
methionin
respect
presenc
fetal
calf
serum
dialyz
pb
h
leucin
cimmol
new
england
nuclear
methionin
cimmol
amersham
respect
per
millilit
tgev
purifi
two
sucros
gradient
nacl
first
one
contain
tween
previous
describ
radioimmunoassay
bind
antibodi
viru
determin
radioimmunoassay
ria
tgev
protein
per
well
pb
adsorb
polyvinyl
dispos
flatbottom
plate
titertek
flow
laboratori
overnight
incub
subsequ
step
assay
perform
describ
sanz
et
al
use
rabbit
antiserum
mous
immunoglobulin
amplifi
reaction
protein
develop
assay
titer
ria
defin
maximum
antibodi
dilut
bound
threefold
background
radioact
polyclon
antiserum
tgevspecif
swine
antiserum
induc
immun
minipig
haplotyp
cc
sach
et
al
three
dose
purifi
tgev
complet
freund
adjuv
incomplet
adjuv
salin
solut
serum
titer
ria
ni
monoclon
antibodi
mar
mutant
mab
mabresist
mar
mutant
produc
character
describ
previous
jimenez
et
al
correa
et
al
properti
mab
use
studi
summar
tabl
mar
mutant
isol
neutral
less
fold
byth
homolog
mab
neutral
origin
viru
kinet
neutral
hybridoma
cultur
supernat
titrat
ria
dilut
titer
sampl
hybridoma
tabl
characterist
tgeuspecif
mab
use
studi
first
second
capit
letter
indic
viru
protein
antigen
site
respect
small
letter
indic
subsit
correa
et
determin
equilibr
volum
viru
x
pfu
ad
mab
indic
time
sampl
dilut
pb
fetal
calf
serum
immedi
titrat
st
cell
bind
tge
viru
st
c
ell
cell
grown
confluenc
flatbottom
micropl
falcon
plastic
remain
step
perform
nonspecif
bind
site
block
incub
well
min
presenc
pb
contain
mg
bovin
serum
albumin
bsa
per
millilit
block
solut
remov
hlabel
purifi
tgev
x
x
cpm
x
protein
x
ad
per
well
dme
medium
bicarbon
supplement
tim
glutamin
gentami
cinml
mm
hepe
fetal
calf
serum
ph
bind
medium
micropl
incub
min
indic
time
unbound
viru
collect
well
wash
three
time
al
fetal
calf
serum
pb
cellbound
radioact
solubil
pl
nonidet
pb
per
well
sampl
materi
supernat
precipit
trichloroacet
acid
radioact
evalu
liquid
scintil
techniqu
determin
inhibit
bind
viru
st
cell
induc
mab
assay
perform
describ
except
sampl
pl
indic
amount
antibodi
incub
min
vol
label
viru
mixtur
incorpor
well
percentag
specif
bind
bind
label
viru
cell
inhibit
unlabel
viru
obtain
presenc
inhibitor
mab
calcul
formula
bind
cpm
pm
cpm
radioact
associ
cell
presenc
absenc
inhibitor
mab
respect
radioact
associ
cell
presenc
excess
unlabel
viru
radioact
bound
within
differ
batch
viru
rang
total
label
viru
ad
cell
amount
taken
refer
calcul
bind
inhibit
differ
antibodi
competitor
viru
intern
tgev
st
cell
intern
tgev
bind
st
cell
correl
intern
studi
st
cell
monolay
grown
microtest
plate
costar
mixtur
slabel
purifi
viru
x
cpm
x
x
antibodi
dilut
gl
bind
medium
incub
min
ad
well
incub
min
unless
otherwis
indic
rock
platform
co
incub
plate
cool
ice
supernat
collect
cell
wash
bind
medium
supernat
combin
determin
amount
cellassoci
viru
monolay
rins
twice
bind
medium
cellassoci
radioact
determin
solubil
monolay
nonidet
pb
tcainsolubl
radioact
determin
sampl
supernat
well
cell
monolay
determin
intern
viru
bound
cell
monolay
wash
tge
coronaviru
neutral
mechan
mm
citric
acid
mm
kci
mm
nacl
ph
min
immedi
wash
second
time
bind
medium
highland
etal
radioact
determin
indic
tgev
neutral
mab
major
tgev
neutral
fig
individu
murin
mab
first
min
reaction
follow
exponenti
declin
surviv
viru
follow
secondphas
reaction
decreas
rate
neutral
leav
case
persist
fraction
remain
constant
hr
incub
result
shown
extent
neutral
first
minut
reaction
similar
obtain
fig
viru
adsorpt
period
reduc
min
extent
viru
neutral
function
mab
fig
mab
relat
concentr
fig
b
cultur
supernat
contain
mab
e
neutral
viru
infect
dilut
mab
reduc
infect
virtual
respect
neutral
tgev
mab
revers
fold
tabl
dilut
virusantibodi
complex
incub
allow
dissoci
indic
tgev
neutral
revers
process
character
tgev
mar
mutant
deriv
ria
neutral
use
mab
fig
show
mab
exampl
mab
b
bound
neutral
origin
strain
tgev
also
bound
neutral
mar
mutant
indic
neutral
requir
simpl
bind
antibodi
critic
epitop
determin
mab
specif
differ
antigen
subsit
involv
tgev
neutral
cooper
process
inactiv
possibl
binari
combin
satur
amount
six
mab
bind
three
antigen
subsit
subsit
aa
mab
subsit
ab
mab
subsit
ac
mab
studi
neutral
pair
mab
test
result
nonsignific
cooper
contrast
site
aspecif
mab
combin
mab
specif
site
differ
site
r
wood
r
wesley
l
enjuan
unpublish
result
synergist
effect
observ
produc
increas
nj
ni
obtain
best
neutral
mab
individu
use
result
shown
satur
reach
plateau
min
afterth
reaction
start
fig
free
viru
still
avail
bind
specif
inhibit
excess
unlabel
viru
ni
determin
either
immedi
neutral
viru
dilut
virusantibodi
mixtur
pb
fetal
calf
serum
incub
hr
decreas
ni
determin
subtract
ni
virusantibodi
mixtur
dilut
incub
hr
allow
dissoci
complex
ni
forth
mixtur
immedi
titrat
ble
best
inhibit
site
aspecif
mab
follow
site
site
b
site
c
specif
mab
expect
mand
nspecif
mab
inhibit
bind
gener
direct
correl
block
activ
mab
capabl
neutral
viru
observ
tabl
mab
b
low
neutral
activ
ni
inhibit
bind
possibl
larg
igm
isotyp
consequ
proxim
epitop
bound
mab
determin
recogn
cellular
receptor
effect
antibodytoviru
ratio
tgev
neutral
inhibit
virustocel
bind
studi
fig
b
interestingli
mab
specif
two
critic
antigen
subsit
protein
inhibit
bind
tgev
st
cell
concentr
neutral
viru
infect
indic
two
activ
mab
bind
inhibit
neutral
split
intern
hr
incub
fig
viru
intern
proceed
min
delay
reach
maximum
hr
later
viru
intern
temperatur
depend
fig
maxim
viru
intern
specif
receptor
process
effici
inhibit
excess
unlabel
viru
site
aspecif
mab
e
mab
specif
site
e
fig
tgev
neutral
observ
fig
low
antibodi
concentr
dilut
slightli
prevent
intern
viru
increas
viru
bind
cell
intermedi
antibodi
concentr
dilut
antibodi
inhibit
mainli
intern
littl
block
bind
high
antibodi
concentr
dilut
lower
intern
bind
inhibit
extens
fold
neutral
observ
mab
specif
three
subsit
glycoprotein
still
neutral
viru
cell
associ
tabl
condit
viru
expos
cell
surfac
sinc
detach
lowph
buffer
see
materi
method
fig
may
determin
correl
inhibit
bind
intern
neutral
tgev
polyclon
antibodi
effect
differ
antiserum
concentr
paramet
determin
result
fig
show
inhibit
intern
bind
extens
neutral
observ
antibodi
dilut
e
inhibit
either
bind
intern
observ
furthermor
higher
dilut
antiserum
produc
increas
bind
intern
viru
fig
signific
neutral
observ
although
dilut
control
serum
induc
small
increas
bind
viru
increas
intern
neutral
note
shown
tgev
neutral
antibodi
singl
specif
revers
reaction
follow
second
phase
decreas
neutral
rate
case
onset
persist
fraction
addit
predomin
mechan
tgev
neutral
determin
neutral
tgev
mab
occur
rapidli
min
adsorpt
viru
perform
dilut
antibodyviru
mixtur
shown
tabl
neutral
tgev
mab
use
could
revers
incub
dilut
mixtur
never
increas
fact
time
adsorpt
reduc
sun
et
al
min
signific
decreas
extent
neutral
observ
critic
epitop
must
certain
structur
context
effect
neutral
fig
sinc
although
certain
epitop
present
mar
mutant
demonstr
bind
mab
virus
fig
neutral
fig
contrast
neutral
wildtyp
viru
probabl
structur
antigen
subsit
chang
mutant
similar
phenomenon
describ
polioviru
loss
neutral
function
epitop
necessarili
result
loss
antibodybind
capac
epitop
bind
mab
neutral
wt
viru
neutral
mar
mutant
exist
natur
mahoney
sabin
virus
blondel
et
neutral
tgev
mab
revers
dilut
tabl
contrast
neutral
polioviru
appar
irrevers
process
revers
dilut
icenogl
et
result
probabl
reflect
avid
antibodi
use
case
neutral
reaction
revers
viral
system
mandel
littl
cooper
tgev
neutral
observ
site
aspecif
mab
even
mab
react
differ
antigen
subsit
use
result
seem
logic
bind
site
aspecif
mab
prevent
bind
second
one
specif
site
contrast
synergist
effect
observ
mab
bind
differ
site
involv
neutral
result
shown
could
expect
mab
interfer
bind
viru
coronavirus
mous
hepat
viru
infecti
bronchiti
viru
attach
host
cell
glycoprotein
sturman
holm
cavanagh
davi
holm
et
similarli
must
also
case
tgev
mab
specif
glycoprotein
mab
specif
n
protein
inhibit
bind
st
cell
mab
specif
antigen
site
best
inhibitor
bind
tabl
suggest
domain
recogn
cellular
receptor
st
cell
must
locat
spatial
close
site
studi
relationship
neutral
bind
inhibit
tgevspecif
mab
tabl
essenti
show
first
bind
viru
st
cell
specif
three
type
result
indic
case
bind
satur
fig
ii
bind
hlabel
slabel
viru
inhibit
higher
concentr
unlabel
one
serolog
unrel
mous
hepat
coronavi
fig
intern
viru
defin
amount
radiolabel
virion
remain
cell
associ
incub
presenc
ph
buffer
use
lowph
buffer
differenti
expos
intern
virion
previous
describ
huang
wagner
highland
etal
tgev
system
assay
valid
follow
base
fig
cell
viabil
affect
incub
ph
buffer
ii
incub
virion
bound
intern
temperatur
cellbound
virion
detach
cell
pb
remov
ph
buffer
iii
incub
virion
intern
incub
virion
detach
wash
either
pb
ph
buffer
iv
amount
viru
remain
cell
associ
treatment
ph
buffer
depend
temperatur
incub
maximum
expect
intern
virion
v
intern
defin
procedur
specif
process
sinc
inhibit
mab
specif
site
site
c
unlabel
tgev
serolog
unrel
mhv
correl
establish
radiolabel
infecti
virion
follow
basi
decreas
fold
virion
infect
detect
absenc
antibodi
normal
around
total
radioact
ad
fig
indic
virion
neutral
bind
radiolabel
virion
cell
inhibit
simplest
explan
neutral
condit
due
block
bind
possibl
bind
infecti
viru
inhibit
would
repres
minor
proport
exclud
nevertheless
seem
unlik
sinc
noninfecti
viru
render
noninfecti
differ
defect
larg
proport
virion
specif
bound
cell
obvious
infecti
virion
includ
among
result
strongli
suggest
infecti
noninfecti
virion
function
spike
protein
mediat
bind
viru
cell
limit
deriv
inhabl
follow
isol
infecti
virion
accept
studi
analyz
interact
virus
cell
electron
microscopi
use
radiolabel
virion
fuller
spear
fulleret
highland
et
al
miller
huttfletch
case
observ
virion
radioact
correspond
noninfecti
particl
number
antibodi
molecul
interact
viru
particl
neutral
estim
assum
coronaviru
particl
infecti
valu
estim
x
x
immunoglobulin
molecul
mab
c
pervirion
high
antibodi
kinet
tgev
bind
intern
optimum
temperatur
process
specif
inhibit
bind
intern
slabel
purifi
tgev
studi
st
cell
monolay
grown
plate
ad
viru
see
materi
method
incub
immedi
cool
plate
ice
indic
time
remov
unbound
viru
wash
bind
medium
determin
cellassoci
viru
u
ph
buffer
determin
intern
viru
b
intern
slabel
purifi
tgev
st
cell
monolay
grown
plate
determin
indic
temperatur
presenc
undilut
hybridoma
supernat
contain
tgev
protein
site
cspecif
mab
shade
column
site
aspecif
mab
c
c
hatch
column
excess
unlabel
tgev
blank
column
extent
intern
affect
presenc
control
coronaviru
mhv
absenc
mab
medium
result
shown
maximum
radioact
bound
intern
absenc
antibodi
compet
viru
set
bind
intern
respect
usual
respect
total
radioact
ad
toviru
ratio
undilut
supernat
assum
tgev
spike
glycoprotein
per
virion
number
influenza
viru
dimmock
high
antibodi
viru
ratio
molecul
mab
per
glycoprotein
could
interfer
virustocel
bind
analyz
neutral
tgev
mab
three
situat
consid
respect
antibodytoviru
ratio
high
ratio
sun
et
al
good
correl
neutral
activ
mab
abil
inhibit
bind
tgev
st
cell
mast
mab
fit
correl
tabl
indic
high
antibodi
concentr
bind
viru
cellular
receptor
prevent
pseudoneutr
result
steric
hindranc
probabl
occur
mandel
observ
confirm
studi
effect
differ
mab
concentr
bind
fig
fig
expect
neutral
slightli
effici
phenomenon
observ
tgev
regular
basi
intermedi
antibodytoviru
ratio
predomin
caus
viru
neutral
probabl
inhibit
intern
viru
bound
accumul
cell
surfac
fig
result
shown
low
antibodytoviru
ratio
fig
tgev
neutral
fold
viru
still
cell
associ
indic
step
inhibit
dilut
ought
differ
bind
concentr
bind
viru
st
cell
clearli
increas
probabl
result
aggr
relationship
neutral
tgev
mab
inhibit
bind
intern
st
cell
purifi
tgev
incub
min
indic
dilut
mab
virusmab
mixtur
ad
st
cell
monolay
grown
plate
incub
hr
cellassoci
intern
viru
determin
wash
monolay
either
bind
medium
ph
buffer
respect
residu
infect
determin
viru
prepar
perform
dilut
incub
immedi
use
infect
cell
monolay
grown
plate
result
shown
repres
averag
valu
three
experi
individu
consid
gave
pattern
respect
neutral
activ
mab
determin
two
procedur
first
adsorb
differ
number
pfu
cell
incub
min
ad
mab
incub
min
remov
excess
mab
wash
medium
ad
cultur
medium
incub
plaqu
develop
ii
mix
mab
viru
incub
min
ad
mixtur
cell
incub
differ
number
pfu
mab
min
cell
monolay
wash
medium
proceed
tgev
low
antibodi
concentr
due
block
bind
viru
bound
could
still
neutral
fact
tgev
alreadi
bound
st
cell
neutral
mab
tabl
condit
viru
protect
cell
dissoci
ph
fig
highland
al
access
mab
prevent
extens
neutral
observ
viru
interact
first
antibodi
tabl
result
low
antibodytoviru
ratio
fig
suggest
neutral
due
inhibit
viru
intern
neutral
detect
ratio
could
part
result
aggreg
portion
viru
caus
mab
c
c
determin
electron
microscopi
result
shown
also
alter
observ
viru
structur
could
respons
inhibit
intern
step
take
place
viral
system
adenoviru
neutral
due
block
replic
cycl
step
occur
intern
fact
adenovirion
alreadi
attach
hela
cell
could
neutral
antihexon
antipenton
base
antisera
prevent
intern
wohlfart
wohlfart
et
al
similarli
influenza
viru
neutral
satur
amount
monoclon
igg
direct
hemagglutinin
enter
cell
undergo
primari
secondari
uncoat
vivo
rigg
et
al
herp
simplex
viru
system
mab
describ
potent
neutral
activ
associ
inhibit
viru
adsorpt
inhibit
intern
fuller
spear
fulleret
viru
neutral
bind
assay
conduct
viru
mab
stock
similar
condit
one
differ
assay
neutral
virusantibodi
mixtur
dilut
condit
neutral
viru
might
dissoci
antibodi
recov
infect
tabl
result
impli
neutral
valu
present
minimum
correl
neutral
bind
inhibit
even
lowerthan
one
shown
fig
strengthen
conclus
direct
inhibit
bind
mechan
viral
neutral
low
antibodytoviru
ratio
summari
neutral
tgev
probabl
coronavirus
may
consequ
inhibit
sever
step
replic
cycl
virus
may
neutral
antibodi
molecul
bound
per
virion
small
aggreg
detect
slight
inhibit
intern
block
step
would
take
place
intern
intermedi
antibodi
viru
ratio
inhibit
intern
predomin
mechan
neutral
studi
perform
high
antibodi
concentr
bind
viru
prevent
step
take
place
bind
inhibit
appear
mechan
neutral
studi
perform
indic
legend
fig
circl
squar
triangl
indic
cellassoci
viru
viru
intern
residu
infect
respect
treatment
tgevspecif
antiserum
full
symbol
serum
nonimmun
anim
blank
symbol
studi
inhibit
virustocel
bind
intern
use
mab
permit
select
inhibit
step
viru
cycl
fig
polyval
antibodi
fig
differenti
possibl
murin
result
shown
porcin
polyval
antisera
neutral
tgev
also
inhibit
bind
viru
st
cell
high
concentr
contrast
lower
antibodytoviru
ratio
viru
could
neutral
polyclon
antiserum
without
induc
inhibit
bind
intern
result
appear
varianc
nguyen
et
al
report
neutral
tgev
polyval
antibodi
due
inhibit
intern
grate
j
garcia
critic
review
manuscript
c
sanchez
j
paladin
excel
technic
assist
qs
g
c
j
b
f
g
c
hold
fellowship
ministri
educ
scienc
investig
fund
grant
consejo
superior
de
investigacion
cientifica
comis
interministeri
de
ciencia
tecnologia
european
f
sun
et
al
econom
commun
project
bap
e
gr
fundacion
ramon
arec
